Clinical Efficacy and Safety of Bempedoic Acid in High Cardiovascular Risk Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Bempedoic Acid (BA) is the new addition to lipid-lowering medications. This systematic review and meta-analysis of randomized controlled trials (RCTs) assess the clinical efficacy and safety of BA in high cardiovascular (CV) risk patients along with its effects on low-density lipoprotein cholesterol...

Full description

Saved in:
Bibliographic Details
Published in:Current problems in cardiology 2023-12, Vol.48 (12), p.102003-102003, Article 102003
Main Authors: Uddin, Naseer, Syed, Abdul Ahad, Ismail, Syed Muhammad, Ashraf, Muhammad Talal, Khan, Muhammad Khuzzaim, Sohail, Affan
Format: Article
Language:English
Subjects:
Bempedoic Acid
Cardiovascular Disease
Cholesterol, LDL
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
MACE
Meta-analysis
Mortality
Randomized Controlled Trials as Topic
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bempedoic Acid (BA) is the new addition to lipid-lowering medications. This systematic review and meta-analysis of randomized controlled trials (RCTs) assess the clinical efficacy and safety of BA in high cardiovascular (CV) risk patients along with its effects on low-density lipoprotein cholesterol (LDL-C) and total cholesterol. PubMed, Google Scholar, Cochrane Central Register of Controlled Trials, Embase, and ClinicalTrials.gov were searched for RCTs comparing BA with placebo, reporting CV outcomes. Seven RCTs with a total of 17,816 patients were selected for the analysis. Results showed that BA significantly reduced the risk of MACE (RR 0.87, 95%CI 0.80 to 0.94; p=0.007), non-fatal myocardial infarction (RR 0.73; 95%CI 0.62 to 0.85; P
ISSN:0146-2806
1535-6280
DOI:10.1016/j.cpcardiol.2023.102003